Search Results

Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.

• Authors : Lv L; Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA. Electronic address: .; Brady BL

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood

• Source: Primary care diabetes [Prim Care Diabetes] 2024 Oct; Vol. 18 (5), pp. 511-517. Date of Electronic Publication: 2024 Jul 10.Publisher: Elsevier Country of Publication: England NLM ID: 101463825 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0210

Record details

Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.

• Authors : Petersen J; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Subjects: Caloric Restriction*/Caloric Restriction*/Caloric Restriction*/methods ; Obesity*/Obesity*/Obesity*/metabolism ; Obesity*/Obesity*/Obesity*/drug therapy

• Source: Molecular metabolism [Mol Metab] 2024 Nov; Vol. 89, pp. 102027. Date of Electronic Publication: 2024 Sep 13.Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.

• Authors : Al Refaie A; Section of Internal Medicine, Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100, Siena, Italy.; Division of Internal Medicine I, San Giuseppe Hospital, 50053, Empoli, Italy.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists

• Source: Calcified tissue international [Calcif Tissue Int] 2024 Aug; Vol. 115 (2), pp. 160-168. Date of Electronic Publication: 2024 Jun 12.Publisher: Springer Verlag Country of Publication: United States NLM ID: 7905481 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?

• Authors : Kaplan JM; Department of Internal Medicine, Section of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, One Baylor Plaza, R618, Houston, TX, 77030, USA.; Zaman A

Subjects: Obesity*/Obesity*/Obesity*/drug therapy ; Obesity*/Obesity*/Obesity*/complications ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists

• Source: Current cardiology reports [Curr Cardiol Rep] 2024 Sep; Vol. 26 (9), pp. 1011-1019. Date of Electronic Publication: 2024 Jul 20.Publisher: Current Science Country of Publication: United States NLM ID: 100888969 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.

• Authors : Tanaka K; First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.; Okada Y

Subjects: Glycemic Control*/Glycemic Control*/Glycemic Control*/adverse effects; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

• Source: Scientific reports [Sci Rep] 2022 Jan 07; Vol. 12 (1), pp. 154. Date of Electronic Publication: 2022 Jan 07.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

• Authors : Guarnotta V; Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza 'G. D'Alessandro' (PROMISE), Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Università di Palermo, Italy.; Bianco MJ

Subjects: Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Fibronectins/Fibronectins/Fibronectins/*blood

• Source: Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2021 Oct 28; Vol. 31 (11), pp. 3193-3201. Date of Electronic Publication: 2021 Jul 24.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111474 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.

• Authors : Saraiva JFK; Faculdade de Medicina do Centro de Ciências da Vida - Pontifícia, Universidade Católica de Campinas, Av John Boyd Dunlop, s/n - Jd. Ipaussurama, Campinas, SP, CEP: 13060-904, Brazil.; Franco D

Subjects: Glycemic Control*/Glycemic Control*/Glycemic Control*/adverse effects; Atherosclerosis/Atherosclerosis/Atherosclerosis/*drug therapy ; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Dec 15; Vol. 20 (1), pp. 235. Date of Electronic Publication: 2021 Dec 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

Record details

Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.

• Authors : Aggarwal R; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.; Vaduganathan M

Subjects: Drug Approval* ; United States Food and Drug Administration*; Anti-Obesity Agents/Anti-Obesity Agents/Anti-Obesity Agents/*therapeutic use

• Source: Progress in cardiovascular diseases [Prog Cardiovasc Dis] 2021 Sep-Oct; Vol. 68, pp. 97-98. Date of Electronic Publication: 2021 Sep 21.Publisher: W.B. Saunders Co. [etc.] Country of Publication: United States NLM ID: 0376442 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.

• Authors : Shi Y; Department of Endocrinology, Changzheng Hospital, Naval Medical University, Shanghai, China.; Liu S

Subjects: Body Mass Index* ; Glycemic Control*/Glycemic Control*/Glycemic Control*/adverse effects; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects

• Source: Journal of diabetes [J Diabetes] 2021 Apr; Vol. 13 (4), pp. 353-357. Date of Electronic Publication: 2021 Jan 02.Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Semaglutide (Ozempic) for weight loss.

Subjects: Anti-Obesity Agents/Anti-Obesity Agents/Anti-Obesity Agents/*therapeutic use ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*therapeutic use ; Incretins/Incretins/Incretins/*therapeutic use

• Source: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2021 Apr 05; Vol. 63 (1621), pp. 53-54.Publisher: The Medical Letter Country of Publication: United States NLM ID: 2985240R Publication Model: Print Cited Medium: Internet ISSN:

Record details